Table 2.
Comparison of Clinical Performance Among Three Sample-to-Result Molecular Assays for SARS-CoV-2
| Molecular Assay Platform | Number of Results Obtained versus the Reference RT-PCR Method | |||
|---|---|---|---|---|
| SARS-CoV-2 Wild Type (Non-B.1.1.7) | SARS-CoV-2 VOC (B.1.1.7) | |||
| Positive | Negative | Positive | Negative | |
| BioFire RP2.1 panel | ||||
| Positive | 49 | 0 | 75 | 0 |
| Negative | 1 | 200 | 0 | 200 |
| Cobas Liat System | ||||
| Positive | 50 | 0 | 75 | 0 |
| Negative | 0 | 200 | 0 | 200 |
| Cepheid Xpert Xpress | ||||
| Positive | 50 | 0 | 75 | 0 |
| Negative | 0 | 200 | 0 | 200 |
| Positive percent agreement (95% CI) | 98.0–100% (89.5–100%) | 100% (95.1–100%) | ||
| Negative percent agreement (95% CI) | 100% (98.1–100%) | 100% (98.1–100%) | ||
| Overall percent agreement (95% CI) | 99.6–100% (97.8–100%) | 100% (98.6–100%) | ||